Narayana Hrudayalaya Ltd (NSE:NH)
₹ 1,885.1 +0.10 (+0.01%) Market Cap: 382.86 Bil Enterprise Value: 416.13 Bil PE Ratio: 46.92 PB Ratio: 8.44 GF Score: 93/100

Q3 2026 Narayana Hrudayalaya Ltd Earnings Call Transcript

Feb 17, 2026 / 09:30AM GMT
Release Date Price: ₹1829.1 (-0.42%)

Key Points

Positve
  • Narayana Hrudayalaya Ltd (BOM:539551) reported strong profit growth in its India business for the second consecutive quarter, driven by transformation programs and payer mix optimization.
  • The company has seen significant margin expansion in its India operations, with a 150 to 200 basis point increase year-over-year.
  • The Bangalore cluster experienced strong growth due to high-end robotic surgeries and increased domestic footfalls.
  • The oncology department is the fastest-growing segment and is expected to become a major revenue contributor alongside cardiac services.
  • Narayana Hrudayalaya Ltd (BOM:539551) is focusing on expanding its insurance offerings and integrated care services, which have been well-received in the market.
Negative
  • The company is still facing challenges in achieving break-even for its insurance and clinics business segments.
  • The northern cluster in India experienced softer growth due to receivable issues and increased competition from new hospitals.
  • The UK operations are currently less profitable compared to India and Cayman, with efforts ongoing to improve margins.
  • There is increased competition in the Bangalore market, with new hospitals being established, which may impact short-term profitability.
  • The company faces challenges in the Gurgaon market due to competition from larger hospitals, affecting profitability and patient acquisition.
Operator

Recording.

Nishant Singh
Narayana Hrudayalaya Pvt Ltd - VP & Investor Relations

In progress. Good afternoon, everyone. My name is Nishan Singh, and I welcome you all to the quarter 3 FY26 earnings call of Marana Sahala Limited. To discuss our performance and address all your queries today, we also have with us, Mr. Birrerind Shetty, our Vice Chairman, Doctor Emmanuel Rupert, our CEO and MD, Mr. Sandhya Jayraman, our group CFO, Mr. Venkatesh, our group COO, Doctor Anesh Shetty, MD of our overseas businesses, Mr. Ravi Vishwanath, CEO of NHIC, and Mr. Vivek Agarwal, senior manager in the IR function.

Before we proceed with this call, we would like to remind everyone that the call is being recorded and the transcript of the same should be made available on our website as well as on the stock exchange at a later date. We'd also like to remind you that everything that is being said on this call that reflects any outlook for the future or which can be construed as a forwarding a statement must be viewed in conjunction with the uncertainties and the risks

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot